Diphosphonates

"Diphosphonates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.

Descriptor ID	D004164
MeSH Number(s)	D02.705.429.500
Concept/Terms	Diphosphonates Diphosphonates Bisphosphonates

Below are MeSH descriptors whose meaning is more general than "Diphosphonates".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Organophosphorus Compounds [D02.705]
Organophosphonates [D02.705.429]
Diphosphonates [D02.705.429.500]

Below are MeSH descriptors whose meaning is related to "Diphosphonates".

Below are MeSH descriptors whose meaning is more specific than "Diphosphonates".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Diphosphonates" by people in this website by year, and whether "Diphosphonates" was a major or minor topic of these publications.

Bar chart showing 40 publications over 18 distinct years, with a maximum of 5 publications in 2014 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2003	2	0	2
2004	1	0	1
2005	1	1	2
2007	1	1	2
2008	2	0	2
2009	1	0	1
2010	1	0	1
2011	4	0	4
2012	1	0	1
2013	0	1	1
2014	3	2	5
2015	0	1	1
2016	2	0	2
2017	3	1	4
2018	2	3	5
2019	0	1	1
2020	2	2	4

Below are the most recent publications written about "Diphosphonates" by people in Profiles.

Van Poznak C, Reynolds EL, Estilo CL, Hu M, Schneider BP, Hertz DL, Gersch C, Thibert J, Thomas D, Banerjee M, Rae JM, Hayes DF. Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. Oral Dis. 2022 Jan; 28(1):193-201.

View in: PubMed
Sawamoto K, ?lvarez JV, Herre?o AM, Otero-Espinar FJ, Couce ML, Alm?ciga-D?az CJ, Tomatsu S. Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders. Curr Osteoporos Rep. 2020 10; 18(5):515-525.

View in: PubMed
Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, Dell RM, Adams AL. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020 08 20; 383(8):743-753.

View in: PubMed
Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst. 2020 07 01; 112(7):698-707.

View in: PubMed
Franzone JM, Shah SA, Wallace MJ, Kruse RW. Osteogenesis Imperfecta: A Pediatric Orthopedic Perspective. Orthop Clin North Am. 2019 Apr; 50(2):193-209.

View in: PubMed
Jain M, Tam A, Shapiro JR, Steiner RD, Smith PA, Bober MB, Hart T, Cuthbertson D, Krischer J, Mullins M, Bellur S, Byers PH, Pepin M, Durigova M, Glorieux FH, Rauch F, Lee B, Sutton VR, Nagamani SCS. Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. Genet Med. 2019 02; 21(2):275-283.

View in: PubMed
Berglund JA, Tella SH, Tuthill KF, Kim L, Guthrie LC, Paul SM, Stanton R, Collins MT, Boyce AM. Scoliosis in Fibrous Dysplasia/McCune-Albright Syndrome: Factors Associated With Curve Progression and Effects of Bisphosphonates. J Bone Miner Res. 2018 09; 33(9):1641-1648.

View in: PubMed
Jategaonkar AA, Badhey AK, Sokoya M, Kadakia S, Mudrovich S, Ducic Y. Total mandibulectomy defect in the setting of chronic bisphosphonate use. Am J Otolaryngol. 2018 Sep - Oct; 39(5):649-651.

View in: PubMed
Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Breast Cancer Res Treat. 2018 Aug; 171(1):121-129.

View in: PubMed
Shapiro CL, Himelstein AL. Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer. JAMA Oncol. 2018 04 01; 4(4):585-586.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement